Lipocine Inc. news

A server-rendered, paginated timeline of the latest available company news.

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154
Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 PR Newswire SALT LAKE CITY, June 4, 2026 Live webinar to take place on Friday, June 12, 2026 at 11:00 AM Eastern Time SALT LAKE CITY, June 4, 2026 /PRNewswire/ -- Lipocine Inc. (Nasdaq: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that it will host a virtual Key Opinion Leader (KOL) event on Friday,
PR Newswire · Jun 4, 2026
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting
Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting PR Newswire SALT LAKE CITY, May 19, 2026 SALT LAKE CITY, May 19, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that its Phase 3 clinical data for LPCN 1154 have been selected for oral and poster presentation at the 2026 American Society of Cli
PR Newswire · May 19, 2026
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
BASEL, Switzerland, May 19, 2026 (GLOBE NEWSWIRE) -- Anaveon, a late-stage biotechnology company pioneering precision biologics to reprogram the immune system for the treatment of autoimmune and inflammatory diseases, today announced the appointments of Eric Zanelli, Ph.D., as Chief Scientific Officer and Jill Jene, Ph.D., MBA, as Chief Business Officer. These strategic C-suite additions bring deep scientific, translational, and business development expertise to accelerate Anaveon’s clinical adv
Globe Newswire · May 19, 2026
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase
Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase PR Newswire SALT LAKE CITY, May 18, 2026 SALT LAKE CITY, May 18, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment therapeutics through effective oral delivery, today announced that management will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held Wednesday, May 20, 2026. (https://mma.prnewswir
PR Newswire · May 18, 2026
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
SAN DIEGO, April 06, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Lipocine Inc. (NASDAQ: LPCN). The investigation focuses on Lipocine’s executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Lipocine securities? If you purchased Lipocine securities and suffered losses on your investment, join our investigation now: Click here to join the investigation (https://www.globenewswir
Globe Newswire · Apr 6, 2026

Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154

Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting

Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer

Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase

Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses